Emergent BioSolutions (EBS) Other Non-Current Liabilities (2010 - 2026)

Emergent BioSolutions' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $41.7 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 17.8% year-over-year to $41.7 million in Q1 2026; TTM through Mar 2026 was $41.7 million, a 17.8% increase from a year earlier, with the FY2025 full-year figure at $53.9 million, up 37.85% from the prior year.
• Other Non-Current Liabilities slipped to $41.7 million in Q1 2026 per EBS's latest filing, from $53.9 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $58.5 million in Q2 2022 and bottomed at $23.4 million in Q2 2023.
• The 5-year median for Other Non-Current Liabilities is $39.1 million (2024), against an average of $38.3 million.
• Across the five-year window, Other Non-Current Liabilities soared 1070.0% in 2022 and sank 60.0% in 2023, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $41.5 million in 2022, then slumped by 30.36% to $28.9 million in 2023, then jumped by 35.29% to $39.1 million in 2024, then surged by 37.85% to $53.9 million in 2025, then slipped by 22.63% to $41.7 million in 2026.
• Per Business Quant, the three latest EBS Other Non-Current Liabilities figures stand at $41.7 million (Q1 2026), $53.9 million (Q4 2025), and $42.6 million (Q3 2025).